Autoimmune thyroid disease and thyroid eye disease
Immunovant Sciences GmbH funds clinical research in Graves’ disease, thyroid eye disease, and related thyroid hormone dysregulation, with attention to endocrine and orbital manifestations.
- Graves’ disease
- Thyroid eye disease
- Proptosis
- Thyroid-stimulating hormone and free thyroid hormones
Its research activity also extends to maintaining euthyroidism and evaluating outcomes tied to antithyroid therapy.
Neuromuscular autoimmune disorders
The sponsor is active in studies of generalized myasthenia gravis, including antibody-positive disease, with a focus on muscle weakness and daily function.
- Generalized myasthenia gravis
- AChR antibody-positive disease
- MG-ADL functional outcomes
- Induction and maintenance therapy
These trials reflect interest in clinical measures of strength, activity limitation, and longer-term disease control.
Peripheral nerve inflammation and immune-mediated neuropathy
Immunovant Sciences GmbH supports research in chronic inflammatory demyelinating polyneuropathy, addressing relapse prevention, neurological function, and treatment durability.
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
- Adjusted INCAT neurological assessment
- Relapse prevention
- Long-term safety and tolerability
Some studies include participants receiving immunoglobulin therapy or plasma exchange, indicating interest in treatment settings used in active neuropathic disease.
Systemic rheumatologic and connective tissue disease
The sponsor funds trials in rheumatoid arthritis, primary Sjögren’s disease, and cutaneous lupus erythematosus, spanning inflammatory joint, glandular, and skin involvement.
- ACPA-positive rheumatoid arthritis
- Primary Sjögren’s disease
- Cutaneous lupus erythematosus
- Systemic disease activity and skin disease scores
Clinical outcomes in this area include joint response, systemic activity, and cutaneous inflammation.
